Table 4.

Multivariate analyses for RFS, peritoneal RFS, and OS

Variables	RFS				Peritoneal RFS				OS
	Model with attenuation		Model with SUV		Model with attenuation		Model with SUV		Model with attenuation		Model with SUV
	p value	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)
Histopathology	–	–	–	–	0.008	3.00 (1.25–7.46)	0.010	3.19 (1.21–8.45)	–	–	–	–
T stage
T2		1.00		1.00		1.00		1.00		1.00		1.00
T3	0.035	3.29 (1.09–9.34)	0.037	3.25 (1.08–9.80)	0.135	4.98 (0.61–40.78)	0.063	7.16 (0.90–57.09)	0.158	5.27 (0.65–14.49)	0.312	2.29 (0.46–11.30)
T4	0.005	5.08 (1.66–15.57)	0.003	5.32 (1.73–16.14)	0.025	10.90 (1.35–88.16)	0.026	10.88 (1.32–89.38)	0.006	5.27 (1.24–24.32)	0.010	3.36 (1.15–17.20)
Lymph node metastasis	0.038	3.20 (1.07–9.59)	0.030	3.35 (1.12–10.02)	0.159	3.06 (0.65–14.52)	0.200	2.83 (0.58–13.84)	0.527	1.66 (0.35–7.99)	0.511	1.70 (0.35–8.30)
Tumor size	0.295	1.46 (0.72–2.99)	0.167	1.62 (0.82–3.23)	0.033	3.25 (1.10–9.63)	0.049	3.05 (3.05–9.27)	0.452	1.54 (0.50–4.78)	0.311	1.82 (0.57–5.78)
NLR	0.053	1.93 (0.99–3.79)	0.015	2.21 (1.16–4.19)	0.063	2.68 (0.95–7.57)	0.101	2.28 (0.85–6.09)	0.251	1.72 (0.68–4.32)	0.175	1.89 (0.75–4.77)
SUVmaxT	0.015	2.21 (1.16–4.19)	0.039	2.01 (1.04–3.89)	–	–	–	–	0.012	4.28 (1.24–14.81)	0.139	2.66 (0.73–9.74)
VAT attenuation	0.477	1.28 (0.65–2.53)	–	–	0.008	3.86 (1.47–1.12)	–	–	0.007	3.83 (1.36–10.87)	–	–
VAT SUV	–	–	0.530	1.23 (0.64–2.36)	–	–	0.019	2.99 (1.20–7.48)	–	–	0.004	8.45 (1.97–37.02)

Statistically significant for variables with p < 0.0083 after Bonferroni adjustment

RFS recurrence-free survival, OS overall survival, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SUVmaxT maximum standardized uptake value of primary tumor, VAT visceral adipose tissue, SUV standardized uptake value, CI confidence interval